A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL)
Clinical trial NCT05192486 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05192486
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-08-10
- Primary completion
- 2025-12-01
- Enrollment
- 12
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.